Muhammad et al. have addressed the issue of suitable tumor targets with a newly developed tandem CAR (TanCAR) that targets both ephrin type-A receptor 2 (EphA2) and interleukin-13 receptor subunit α-2 (IL-13Rα2) in glioblastoma (GBM) models. Here, EPHA2 is linked to neoplasm.